Tocagen Inc (NASDAQ:TOCA) released its earnings results on Wednesday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.04, Morningstar.com reports. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million.

Shares of Tocagen (TOCA) traded up 0.18% during trading on Thursday, reaching $11.00. 46,460 shares of the company were exchanged. Tocagen has a 1-year low of $9.68 and a 1-year high of $17.95. The firm’s market capitalization is $217.88 million. The company’s 50-day moving average is $11.31 and its 200 day moving average is $13.61.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/tocagen-inc-toca-posts-quarterly-earnings-results-misses-estimates-by-0-04-eps/1470705.html.

Several research firms have recently issued reports on TOCA. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 target price on shares of Tocagen in a report on Tuesday, July 25th. Leerink Swann initiated coverage on shares of Tocagen in a report on Monday, May 8th. They set a “market perform” rating and a $19.00 target price for the company. Finally, Evercore ISI restated an “outperform” rating and issued a $28.00 price objective on shares of Tocagen in a report on Tuesday, May 9th.

A number of large investors have recently made changes to their positions in the stock. TD Asset Management Inc. purchased a new stake in shares of Tocagen during the second quarter valued at $158,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Tocagen during the second quarter valued at $165,000. Teachers Advisors LLC purchased a new stake in shares of Tocagen during the second quarter valued at $181,000. Wells Fargo & Company MN purchased a new stake in shares of Tocagen during the second quarter valued at $183,000. Finally, Alps Advisors Inc. purchased a new stake in shares of Tocagen during the second quarter valued at $215,000. Institutional investors own 0.08% of the company’s stock.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.